Testing adebrelimab with chemo or SHR-8068 for certain advanced stomach cancers
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests a new immunotherapy drug (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for a specific type of advanced stomach cancer that has a genetic marker called dMMR or MSI-H. The goal is to see if these combinations can make the tumor shrink enough to be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of stomach or junction cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).
- Your cancer must be at a stage where the doctor thinks it can be completely removed with surgery.
- You must be able to swallow tablets.
- You must not have had any prior treatment for your stomach cancer (except a bypass surgery for blockage).
- You must not have active infections like hepatitis B or C, HIV, or autoimmune disease needing strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called adebrelimab along with chemotherapy and radiation before surgery for stomach or gastroesophageal junction cancer that has spread locally or has limited spread. It aims to see if this combination can help make the tumor removable and improve outcomes.
This trial tests a new treatment combination for locally advanced stomach cancer. First, you would receive a heated chemotherapy wash inside your abdomen (HIPEC). Then you would get the immunotherapy drug serplulimab plus standard chemotherapy (SOX or XELOX) before surgery, to shrink the tumor and improve outcomes.
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (capecitabine and oxaliplatin) for people with stomach cancer or cancer where the stomach meets the esophagus. It aims to see if this combination is safe and effective for patients who have not had prior treatment for advanced disease.
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.